LIVE EVENT
GCN Investor Conference in Newport Beach, CA
OCT 15 · NEWPORT BEACH, CA
LIVE EVENT
One of the world's oldest universities, now a major source of life sciences and deep tech spinouts through a dedicated commercialisation model.
The University of Oxford has built one of the most productive research commercialisation operations in Europe. Oxford University Innovation manages the university's intellectual property, while Oxford Science Enterprises provides patient capital specifically for Oxford spinouts.
That two-part structure — a technology transfer office paired with a dedicated investment vehicle — is a deliberate answer to the historic European problem of research not reaching market.
Oxford's spinout activity is concentrated in therapeutics, diagnostics, quantum computing, and artificial intelligence. The Oxford Foundry supports student and alumni ventures more broadly.
The wider Oxford-Cambridge corridor has become the United Kingdom's primary deep technology cluster, with substantial laboratory and incubator capacity.
Oxford spinouts include Oxford Nanopore Technologies in genomic sequencing and Vaccitech, whose vaccine technology underpinned the Oxford-AstraZeneca vaccine. Output is weighted heavily towards science-based ventures rather than consumer software.
Oxford Science Enterprises is the anchor investor for university spinouts. The broader UK base includes IP Group, Parkwalk Advisors, and London-based venture firms, with strong government support through Innovate UK.
GCN’s global network includes millions of startups and founders and a broad community of investors, creating opportunities to discover potential connections across university communities.
.webp){kind=logo}
.png)
.png)